Xylazine is a structural analog of clonidine and an α₂-adrenergic receptor agonist, sold under many trade names worldwide, most notably the Bayer brand name Rompun, as well as Anased, Sedazine and Chanazine. It is an imidazoline derivative used primarily in veterinary medicine for sedation, analgesia and muscle relaxation, typically administered as the hydrochloride salt by intramuscular or intravenous injection; onset is rapid and the clinical duration is dose dependent, commonly from under an hour to several hours. Pharmacodynamically, xylazine produces central nervous system depression through presynaptic α₂-receptor activation that reduces norepinephrine release and sympathetic outflow, and it has predictable cardiovascular effects including bradycardia and variable blood pressure responses, as well as respiratory depression at higher doses. Metabolism is hepatic with renal excretion of metabolites, and quality control for pharmaceutical formulations centers on assay by HPLC or LC-MS, identity confirmation by NMR and IR, and control of residual solvents and inorganic counterions.
Parent: Lidocaine/ Ropivacaine/ Mepivacaine/ Bupivacaine
Pharmaceutical grade xylazine hydrochloride is routinely manufactured and released with high assay purity, commonly greater than 98 percent by validated HPLC methods, and product specifications typically limit total unidentified impurities to low parts per hundred or parts per thousand levels with individual impurities controlled at 0.1 to 0.5 percent depending on the regulatory monograph and risk assessment. Typical related compounds and potential impurities include unreacted or partially reacted precursors such as 2,6-dimethylaniline, imidazoline byproducts and positional isomers, N-oxidized or dealkylated derivatives, plus residual solvents and inorganic salts from manufacture; structurally related active α₂-adrenergic agonists include clonidine, medetomidine, dexmedetomidine and romifidine, while common pharmacologic antagonists are tolazoline, yohimbine and atipamezole. Release and stability testing generally employ HPLC with diode array or MS detection, LC-MS/MS for trace-level profiling, GC for volatile impurities and compendial microbiological and particulate tests where applicable.
Xylazine functions as a potent α₂-adrenergic receptor agonist that produces sedation, analgesia and muscle relaxation by decreasing presynaptic norepinephrine release and reducing sympathetic tone; it is used mainly in veterinary practice as a sedative and adjunct to anesthesia and also affects cardiovascular and respiratory systems in a dose dependent manner.
There is no universal human approved antidote, but in veterinary practice α₂-adrenergic antagonists such as yohimbine, tolazoline and atipamezole are used to reverse xylazine effects; care is supportive and reversal agent choice and dosing must be determined by a veterinarian or clinician familiar with the species and clinical context.
Xylazine is not included in routine clinical or workplace immunoassay drug panels for common drugs of abuse, but it can be detected if specifically targeted by confirmatory methods such as LC-MS or LC-MS/MS; toxicology laboratories can include xylazine and its metabolites in targeted screens when clinically or forensically indicated.
